SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile

Interventions

DRUG: SER-109
DRUG: Placebo

Sponsor

Seres Therapeutics, Inc.

Collaborators

[object Object]